What is the market capitalization of Genelux Corporation?

Genelux Corporation (GNLX) has a market capitalization of approximately 134,521,248 USD.

How many ETFs hold GNLX?

GNLX is held by 1 ETFs tracked on Investir en Bourse.

Where can I buy GNLX in Canada?

GNLX can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

GNLX

Genelux Corporation

Genelux Corporation (GNLX) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 135 million USD (micro-cap).

Details

Price3.00 USD

Market cap134.52 M USD

Payout ratio0.00%

ROE-127.28%

Debt / Equity10.88%

SectorHealthcare

Websitegenelux.com

Updated 5h ago

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.